

Mouse CD11b/Integrin alpha M Alexa Fluor® 350-conjugated Antibody

Monoclonal Rat IgG_{2B} Clone # M1/70

Catalog Number: FAB1124U
100 µg

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse CD11b/Integrin αM. Cross-reaction with human CD11b/Integrin αM has been reported (1, 2).
Source	Monoclonal Rat IgG _{2B} Clone # M1/70
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Con A-activated C57BL/10 splenocytes
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Mouse splenocytes

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

The Integrin family proteins are heterodimeric transmembrane receptors composed of an α and a β subunit. The Integrin αM subunit, also known as MAC-1α subunit or CD11b, combines with the Integrin β2 subunit (CD18) to form the non-covalent heterodimer Integrin αM/β2, also known as MAC-1 and complement receptor type 3 (CR3). Integrin αM/β2 is expressed on granulocytes, macrophages, dendritic cells and natural killer cells. Upon activation, αM/β2 can bind several ligands (including ICAM-1, fibrinogen, and the C3 complement fragment, C3bi) to mediate phagocyte adhesion, migration and ingestion of complement-opsonized particles.

References:

1. Beller, D.J. *et al.* (1982) J. Exp. Med. **156**:1000.
2. Ault, K.A. and T.A. Springer (1981) J. Immunol. **126**:359.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.